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According to the motivational priming hypothesis, unpleasant stimuli activate the 
motivational defense system, which in turn promotes congruent affective states such 
as negative emotions and pain. The question arises to what degree this bottom–
up impact of emotions on pain is susceptible to a manipulation of top–down-driven 
expectations. To this end, we investigated whether verbal instructions implying pain 
potentiation vs. reduction (placebo or nocebo expectations)—later on confirmed by 
corresponding experiences (placebo or nocebo conditioning)—might alter behavioral and 
neurophysiological correlates of pain modulation by unpleasant pictures. We compared 
two groups, which underwent three experimental phases: first, participants were either 
instructed that watching unpleasant affective pictures would increase pain (nocebo 
group) or that watching unpleasant pictures would decrease pain (placebo group) relative 
to neutral pictures. During the following placebo/nocebo-conditioning phase, pictures 
were presented together with electrical pain stimuli of different intensities, reinforcing the 
instructions. In the subsequent test phase, all pictures were presented again combined 
with identical pain stimuli. Electroencephalogram was recorded in order to analyze 
neurophysiological responses of pain (somatosensory evoked potential) and picture 
processing [visually evoked late positive potential (LPP)], in addition to pain ratings. In the 
test phase, ratings of pain stimuli administered while watching unpleasant relative to neutral 
pictures were significantly higher in the nocebo group, thus confirming the motivational 
priming effect for pain perception. In the placebo group, this effect was reversed such 
that unpleasant compared with neutral pictures led to significantly lower pain ratings. 
Similarly, somatosensory evoked potentials were decreased during unpleasant compared 
with neutral pictures, in the placebo group only. LPPs of the placebo group failed to 
discriminate between unpleasant and neutral pictures, while the LPPs of the nocebo 
group showed a clear differentiation. We conclude that the placebo manipulation already 
affected the processing of the emotional stimuli and, in consequence, the processing of 
the pain stimuli. In summary, the study revealed that the modulation of pain by emotions, 
albeit a reliable and well-established finding, is further tuned by reinforced expectations—
known to induce placebo/nocebo effects—which should be addressed in future research 
and considered in clinical applications.
Keywords: placebo and nocebo effects, emotion processing, psychological pain modulation, late positive 
potential, somatosensory evoked potential
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INTRODUCTION
The processing of pain is prone to a variety of psychological 
variables, such as the affective state of an individual [for an 
overview, see Ref. (1)]. In this vein, it was demonstrated that 
emotions, induced for instance by a threat manipulation (2) or 
by emotionally relevant stimuli, modulate pain processing (3–6). 
In an earlier study, Kenntner-Mabiala and colleagues presented 
affective pictures for about 6 s to participants while they applied 
brief painful electric stimuli and registered pain ratings plus the 
somatosensory evoked potential (SEP) (7, 8). Results suggest that 
emotions modulate early pain processing as unpleasant pictures 
resulted in increased pain ratings and increased amplitudes of the 
early N1 component of the SEP relative to positive pictures. Other 
studies indicate that expectations regarding the characteristics 
of an upcoming pain stimulus also determine the processing of 
nociceptive stimulation and the resulting pain perception (9, 10). 
The same is true for placebo and nocebo effects on pain; however, 
here, expectations focus on the effect of an intervention, which 
is expected to decrease (placebo) or increase pain (nocebo) 
(10–12). Expectations causing placebo and nocebo effects can 
be induced by verbal instructions suggesting a pain-modulating 
effect and/or by the actual experience of pain relief or pain 
exacerbation (placebo/nocebo conditioning) associated with a 
certain treatment or—experimental—intervention (13–17).
In a recent study, we investigated the respective contribution 
of expectations and prior experiences on the formation of placebo 
effects. To this end, we introduced a new, completely psychological 
placebo manipulation, which ensured that participants had not 
encountered the placebo agent before and thus had no a priori 
expectation. We employed a common approach in placebo and 
nocebo research that is a placebo/nocebo instruction followed 
by a reinforcing conditioning phase, during which placebos were 
combined with lower and nocebos with stronger pain stimuli. 
Three experimental conditions were compared: Participants 
were either only informed of an analgesic/pro-algesic effect they 
were about to encounter, or participants actually experienced 
different levels of pain in a conditioning procedure, or participants 
received both, an instruction informing about a pain-modulating 
effect, which received support during a subsequent conditioning 
phase. We found that the latter condition, i.e., expectation plus 
concordant conditioning, was capable in modifying subjective and 
physiological indices of pain, even though the placebo/nocebo 
manipulation was lacking pharmacological plausibility, since we 
instructed participants that “watching certain black and white 
stripe patterns were found to have a pain augmenting/easing 
effect,” respectively (18). These findings corroborate the critical 
role of higher-order cognitions for the modulation of pain.
Placebo and nocebo effects, however, are by no means 
restricted to pain. Significant modifications have been found 
for various somatic symptoms (12) and also for the perception 
of emotions. For example, Petrovic and colleagues found that 
subjective and neuronal responses to unpleasant affective 
pictures were reduced if participants believed they had received 
an anxiolytic medication (19). Based on the involved brain areas, 
the authors assume similar underlying mechanisms in placebo 
effects altering emotion and pain alike. More recently, Schienle 
and colleagues (20) demonstrated reduced feelings of disgust 
paralleled by reduced insular activation when participants 
thought they took a herbal drug against disgust symptoms. In 
a related manner, findings from research on reversal learning 
show placebo- and nocebo-like effects on emotion processing. 
For instance, threat responses following the presentation of 
previously established conditioned threat cues (CS+), which were 
paired with aversive electrical stimuli, are reduced, if participants 
receive a verbal instruction that the cue is no longer indicative 
of danger (21). Similarly, although the presentation of emotional 
facial expressions reliably evokes positive or negative affective 
responses in an observer, verbal instruction about potential 
danger being indicated by a certain face category leads to 
defensive responding irrespective of face valence (e.g., happy or 
fearful faces announcing an aversive outcome) (12). These results 
nicely demonstrate that emotional responses can be shaped top–
down by cognitive representations of superordinate functions.
Interestingly, placebo and nocebo effects often come along 
with emotional responses, such as anticipatory anxiety (nocebo) 
or positive feelings of relief and reward (placebo), which—to some 
degree—might mediate the modulation of (pain) symptoms (22–
24). For instance, Aslaksen and colleagues showed that a nocebo 
instruction suggesting hyperalgesic effects caused by an applied 
cream led to a pain increase, which was meditated by subjective 
and physiological indices of stress (25). However, when applying 
a mere conditioning procedure without explicit placebo or nocebo 
instructions, the role of negative affect might be less relevant (26). 
Just recently, Geers and colleagues found that the experimental 
induction of positive mood by watching a pleasant movie clip was 
capable to block a pain increase by a verbal nocebo suggestion 
(27). Despite all these findings, so far, little research explored the 
interaction of emotions on the one hand and placebo/nocebo 
manipulations on the other when modulating pain.
In the present study, we aimed at investigating whether the 
genuine pain-modulating effect of unpleasant affective pictures 
is sensitive to a placebo or nocebo manipulation. To this end, 
we compared two groups of participants who received either a 
placebo or nocebo manipulation related to unpleasant pictures. 
The nocebo group was instructed that watching unpleasant 
pictures leads to an increased perception of pain in line with 
findings from the literature (nocebo instruction), and during 
a later conditioning procedure, they actually experienced 
relatively more intense pain stimuli when watching the “nocebo” 
pictures. The placebo group was told the exact opposite, namely, 
that unpleasant pictures cause a decreased perception of pain. 
Thereafter, participants experienced relatively less intense pain 
stimuli when watching the “placebo” pictures. In addition to 
pain reports, we measured the electroencephalogram (EEG) 
that allowed us to analyze neurophysiological correlates of pain 
perception (N1 and P2 component of the SEP as mentioned 
earlier) and processing of the emotional pictures by means of 
visually evoked potentials (28). One component of the visually 
evoked potential following the presentation of emotional 
relevant stimuli is the late positive potential (LPP)—a positive 
signal deflection most prominent at centro-parietal electrode 
sites—which was found to be a sensitive measure for emotional 
intensity (arousal) of presented pictures (29–31).
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We hypothesized that unpleasant picture stimuli generally 
increase pain processing; however, this effect is modulated 
by reinforced expectations induced by a placebo/nocebo 
manipulation. Specifically, we expect that a placebo manipulation 
(verbal instruction + placebo conditioning) reduces or even 
reverses the pain-augmenting effect of unpleasant pictures. This 
might lead to lower pain ratings and SEPs for unpleasant compared 
with neutral pictures. Further, the placebo manipulation might 
become evident also in altered neurophysiological correlates of 
unpleasant affective pictures processing, namely, by a lack of LPP 




Forty-two participants were recruited from the University of 
Würzburg and received course credit or €20 as compensation. 
Two participants needed to be excluded due technical problems 
during data acquisition, leaving 40 participants in the final 
analysis, 20 participants in the nocebo group (10 females) and 
20 participants in the placebo group (10 females). All subjects 
had normal or corrected-to-normal vision, reported no current 
or prior history of chronic pain, neurological or psychiatric 
disorders (self-report), and did not take any analgesic medication 
prior to the experiment. Participants first read detailed 
instructions about the experiment and signed the informed 
consent before taking part in the experiment. Participants 
filled out questionnaires on current positive and negative 
affect (Positive Affect/Negative Affect Schedule) (32), on state 
and trait anxiety (State/Trait Anxiety Inventory) (33), on pain 
catastrophizing (Pain Catastrophizing Scale) (34), on sensitivity 
for pain (35), on dispositional optimism and pessimism (Life 
Orientation Test—Revised) (36), and on anxiety of pain related 
symptoms (Pain Anxiety Symptom Scale) (37). Questionnaire 
scores of both groups were similar except for state anxiety, which 
was higher in the placebo group (see Table 1). All procedures 
were approved by the institutional review board of the medical 
faculty of the University of Würzburg.
Visual Stimuli
Participants watched 40 emotional pictures (twice), which were 
drawn from the International Affective Pictures System (38), 
comprising 20 neutral (International Affective Pictures System 
catalog numbers: 2095, 3170, 3180, 3230, 3261, 3500, 3530, 
6212, 6256, 9040, 9050, 9163, 9250, 9300, 9321, 9413, 9419, 
9901, 9921, and 9925) and 20 unpleasant pictures (2038, 2191, 
2383, 2393, 2396, 2514, 2595, 2749, 2850, 2870, 2880, 5390, 
5731, 5870, 7002, 7100, 7130, 7493, 7550, and 7590). Pictures 
were presented for 6 s interleaved by a central fixation cross 
present for 2–3 s (randomized). Picture order was randomized 
with the restriction of no more than two consecutive pictures 
of the same valence. Visual stimuli were projected centrally on 
a screen of 2 × 3.22 m (Powerwall), at 2.0-m distance from the 
participant’s chair.
Electrical Pain Stimulation
Electrical pain stimuli were delivered on the left calf of the 
participants via a surface bar electrode with two stainless steel 
disk electrodes (8-mm diameter, 30-mm spacing), using a 
constant-current stimulator (Digitimer DS7A, Digitimer Ltd., 
Welwyn Garden City, UK). The intensity of the electrical stimulus 
was adjusted to the participants’ individual pain threshold. 
During thresholding, participants were asked to rate electrical 
stimuli of two ascending and two descending series starting from 
0 mA applying steps of ±0.5 mA, respectively, on a 11-point scale 
ranging from 0 (no pain at all) to 10 (unbearable pain). Stimulus 
TABLE 1 | Sample Characteristics.
Measure Nocebo (n = 20) Placebo (n = 20) F p
 m sd m Sd  
Pain Stimulation in mA 2.79 1.01 2.91 1.74 .07 .79  
Pain Stimulus Rating (0–10) 6.25 0.97 6.45 1.19 .34 .56
PANAS Positive 35.50 21.50 32.00 5.46 .50 .48
PANAS Negative 13.95 4.17 12.70 2.36 1.36 .25
STAI State 38.65 5.81 34.30 4.61 6.88 .01 *
STAI Trait 39.20 7.87 35.50 5.99 2.80 .10
LOT 8.45 3.47 7.45 2.48 1.10 .30
PSQ 4.01 1.11 3.96 1.43 .01 .91
PCS 20.80 7.02 17.15 7.16 2.65 .11
PASS-D
Age 23.50 2.48 24.25 2.26 1.01 .32
Post Experimental Survey 
asking for the:
…Effect of Unpleasant Pictures 
on Pain (-4 to +4)
1.90 1.59 -1.90 0.91 < .001 **
…Effect of Neutral Pictures on 
Pain (-4 to +4)
-0.35 0.75 0.90 1.25 < .001 **
Both groups consisted of 10 women and men; PANAS, Positive Affect/Negative Affect Schedule; STAI, State/Trait Anxiety Inventory; LOT, Life Orientation Test; PSQ, Pain Sensitivity 
Questionnaire; PCS, Pain Catastrophizing Scale; PASS-D, Pain Anxiety Symptom Scale; *p < .05; **significant Mann–Whitney U Test.
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intensities rated with a 4 (just noticeable pain) were averaged, 
and 1 mA was added to the final stimulus intensity to reassure 
a moderate pain level. The final stimulation intensity was again 
rated on a 10-point scale (see Table 1). During the experiment, 
two different stimulation intensities were used, which varied with 
regard to the number of consecutive single pulses (train length). 
Low intense stimuli consisted of three square pulses (pulse length 
2 ms) and an inter-pulse interval of 4 ms, high intense stimuli 
instead consisted of 10 square pulses. During the test phase and 
the threshold procedure, high intense stimuli were delivered, and 
during the conditioning phase, both low and high intense stimuli 
were used; see the procedure section for further details.
Electroencephalogram Recording and 
Evoked Potentials
Electrophysiological data were recorded from 32 active electrodes 
(ActiCap; Brain Products, Munich, Germany) with a sampling 
rate of 1,000 Hz, placed according to the international 10–20 
system (C3, C4, CP1, CP2, CP5, CP6, Cz, F3, F4, F7, F8, FC1, 
FC2, FC5, FC6, Fp1, Fp2, Fz, O1, O2, Oz, P3, P4, P7, P8, Pz, T7, 
T8, TP10). FCz was used as online reference, and data were off-
line re-referenced to an average reference. Vertical (above and 
below the left eye) and horizontal (at the outer canthi of both 
eyes) electrooculogram was recorded. Electrode impedance was 
kept below 5 k Ohm, and the online band-pass filter was set to 0.01 
to 250 Hz. Data were collected using a Brain-Amp-MR amplifier 
(Brain Products) and the software Brain Vision Recorder Version 
1.05 together with ActiCap Control Software (Brain Products). 
Off-line EEG analysis was performed using Brain Vision 
Analyzer Version 2.1 (Brain Products). EEG was filtered (0.1–30 
Hz) and corrected for horizontal and vertical ocular artifacts 
(39). Trials exceeding a transition threshold of 50 µV (sample 
to sample) or an amplitude criterion of ±100 µV were excluded 
from further analysis. For the analysis of the picture evoked 
LPP, epochs registered 100 ms before to 2,000 ms after picture 
onset were extracted and baseline corrected with reference to the 
mean baseline interval (100 ms before picture onset). The LPP 
was scored at the parietal electrode Pz and quantified as mean 
activity from 700- to 1,000-ms post picture onset, according to 
visual inspection of the scalp topographies and the literature (28, 
31). For the analysis of the SEP following electrical stimulation, 
epochs registered 100 ms before to 1,000 ms after electrical 
stimulation (first pulse) were extracted, baseline-corrected, and 
averaged analog to the procedure of the LPP. Two components of 
the SEP were analyzed, that is, the N1 and P2, which were scored 
as mean activity at the Cz electrode in a time window from 75 
to 125 ms and 200 to 330 ms, respectively (3, 8). For statistical 
analysis, all event-related potential components were averaged 
per participant across all artifact-free picture and pain epochs of 
the conditioning and test phase, respectively.
Pain Ratings
After each electrical stimulation, pain intensity and 
unpleasantness ratings were obtained using a digital visual 
analog scale. Ratings were converted off-line to values between 
0 and 100. The scale for pain intensity ratings was labeled “not 
painful at all” at the left end and “extremely painful” at the right 
end of the scale, and for pain unpleasantness, the scale ranged 
from “not unpleasant at all” to “extremely unpleasant.”
Procedure
After arrival, participants were assigned to one of the two 
experimental groups (nocebo vs. placebo)—taking into account 
the participants’ gender—following an a priori randomization 
performed by the experimenter. According to the respective 
experimental condition, participants were instructed that 
during the experiment, they would watch a series of unpleasant 
and neutral pictures, which—in line with recent findings in 
the literature—very likely would change their perception of 
concurrently administered painful electrical stimuli. The nocebo 
group was told that unpleasant pictures would increase the 
perception of pain, while neutral pictures had no influence on 
pain at all. The placebo group instead was told that unpleasant 
pictures would result in a decreased perception of pain compared 
with neutral pictures, which would leave the perception of 
pain unchanged. Participants were seated 2.0 m in front of the 
screen and started the experiment. Unbeknownst to them, the 
experiment consisted of two parts, the conditioning phase, 
which was followed without interruption by the test phase. 
During conditioning, participants of the nocebo group watched 
neutral pictures and received the low-intensity pain stimuli and 
unpleasant pictures paired with high-intensity pain stimuli. This 
association was reversed for participants of the placebo group; 
here, participants were administered the low-intensity pain 
stimuli during unpleasant and the high-intensity stimuli during 
neutral picture presentation. Following the logic of previous 
placebo manipulation, this procedure should reassure the 
participants that the instruction they were given in the beginning 
of the experiment actually hold true and pain perception was 
modulated accordingly. During the test phase, participants of both 
groups always received the same, high-intensity pain stimulation, 
combined with neutral and unpleasant pictures (see Figure 1). 
After each trial, participants rated the electrical stimulus for pain 
intensity and unpleasantness. In total, participants completed 80 
trials, which is 20 repetitions of unpleasant and neutral pictures 
per phase. In the end, participants filled out a post experimental 
survey asking how they evaluate the effect of unpleasant and 
neutral pictures on pain using a 9-point scale ranging from +4 
(very pain increasing) to 0 (no effect on pain) to -4 (very pain 
reducing). Stimulus presentation was controlled by the software 
Presentation (Neurobehavioral Systems, Albany, CA, USA).
Statistical Analysis
Pain ratings (pain unpleasantness, pain intensity) and amplitudes 
of the SEP components (N1 and P2) were analyzed separately for 
the conditioning and the test phase. During the conditioning 
phase, a 2 × 2 repeated measures analysis of variance (ANOVA) 
including the within-subjects factors Stimulation Level (high 
vs. low intensity stimulation, irrespective of picture category) 
and the between-subjects factor Group (nocebo vs. placebo) 
was applied. During the test phase, pain responses following 
identical stimulation intensities were analyzed using the within- 
subjects factor Emotion (unpleasant vs. neutral pictures) and 
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the between-subjects factor Group. LPPs were analyzed using 
a 2 × 2 × 2 repeated measures ANOVA including the within-
subjects factor Emotion (unpleasant vs. neutral pictures), Phase 
(conditioning vs. test phase) to capture potential changes 
across the time course of the experiment, and the between-
subjects factor Group. Significant interaction was explored using 
follow-up ANOVAs. The significance level was set to .05 (two-
tailed); for follow-up ANOVAs, a corrected alpha of p < .025 
was considered. As a measure of effect size, we report partial 
η². Normal distribution of the analyzed data can be assumed for 
93% of the variables (Shapiro–Wilk’s tests), due to the robustness 
of the repeated measures ANOVA against violations of data 
normality (40); its usage seems appropriate in the present case.
RESULTS
Pain Ratings—Conditioning Phase
Analysis of pain intensity ratings revealed a significant main 
effect of Stimulation Level F(1, 38) = 152.54, p < .001, ηp² = .80, as 
a result of higher pain ratings following more intense electrical 
stimulation. The interaction of Stimulation Level × Group was 
only marginally significant, F(1, 38) = 3.49, p = .07, ηp² = .08, 
presumably indicating a more pronounced differentiation 
between the two stimulation intensity for the placebo group. 
The factor Group was significant, F(1, 38) = 9.36, p = .004, ηp² = 
.20, due to higher pain ratings in the placebo compared with the 
nocebo group (M = 46.54 vs. M = 30.64), see Figure 2.
Analysis of pain unpleasantness ratings returned a similar 
picture, participants clearly differentiated between the two 
different pain stimuli as indicated by the significant main effect 
of Stimulation Level, F(1, 38) = 113.96, p < .001, ηp² = .75, however 
the interaction of Group x Stimulation was not significant, F(1, 
38) = 0.01, p = .99, ηp² < .01. Again, participants in the placebo 
group reported higher pain in general, F(1, 38) = 10.72, p = .002, 
ηp² = .22, (M = 47.32 vs. M = 31.12), see Figure 2.
Pain Ratings—Test Phase
Analysis of pain intensity ratings revealed a marginal significant 
main effect of Emotion F(1, 38) = 3.66, p = .06, ηp² = .09, which was 
further qualified by a significant interaction of Emotion × Group, 
F(1, 38) = 11.72, p < .001, ηp² = .24. Participants in the placebo group 
rated pain during neutral pictures significantly higher than during 
unpleasant pictures, F(1, 19) = 11.97, p = .003, ηp² = .39, while the 
same comparison failed significance in the nocebo group, F(1, 19) = 
1.41, p = .25, ηp² = .07. The factor Group was also significant, F(1, 
38) = 6.94, p = .01, ηp² = .15, resulting from generally higher pain 
ratings in the placebo group (M = 50.17 vs. M = 35.07), see Figure 3.
Analysis of pain unpleasantness ratings showed no main effect of 
Emotion F(1, 38) = 0.46, p = .50, ηp² = .01; however, the interaction of 
Emotion × Group was significant, F(1, 38) = 31.67, p < .001, ηp² = .45. 
Separate ANOVAs for each group revealed a significant main effect 
of Emotion for both the nocebo F(1, 19) = 22.10, p < .001, ηp² = .54 
and the placebo groups, F(1, 19) = 11.13, p = .003, ηp² = .37. However, 
while participants in the nocebo group rated pain stimuli higher 
FIGURE 1 | Participants were either instructed that watching unpleasant affective pictures would increase pain (nocebo group), or the exact opposite, that watching 
unpleasant pictures would decrease pain (placebo group) relative to neutral pictures. Afterwards, participants underwent placebo/nocebo conditioning, where 
unpleasant and neutral pictures were paired with either high- or low-intensity electrical pain stimuli, in line with the placebo or nocebo instruction provided previously. 
In the following test phase, participants watched the placebo or nocebo and neutral pictures again but received always high-intensity pain stimuli.
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during unpleasant compared with neutral pictures (M = 40.92, vs. 
M = 31.17), participants in the placebo group showed the exact 
opposite pattern, namely, higher pain unpleasantness ratings while 
seeing neutral (M = 58.15) compared with unpleasant pictures (M = 
50.50). Again, the placebo group showed generally higher pain 
unpleasantness ratings compared to the nocebo group, F(1, 38) = 
11.89, p = .001, ηp² = .24, (M = 54.33 vs. M = 36.45), see Figure 3.
Somatosensory Evoked Potentials—
Conditioning Phase
As expected, during the conditioning phase, the physically more 
intense pain stimuli resulted in elevated SEP amplitudes. This 
was true for the early N1 component, F(1, 38) = 73.14, p < .001, 
ηp² = .66, and the subsequent P2, F(1, 38) = 19.11, p < .001, ηp² = 
.34. For both components, neither the interaction [N1, F(1, 38) = 
0.70, p = .41, ηp² = .02; P2, F(1, 38) = 0.91, p = .35, ηp² = .02] nor 
the factor Group reached significance [N1, F(1, 38) = 1.14, p = 
.29, ηp² = .03; P2, F(1, 38) = 0.43, p = .52, ηp² = .01], see Figure 4.
Somatosensory Evoked Potentials—Test 
Phase
Analysis of N1 amplitudes during the test phase—when pain stimuli 
had always the same intensity—revealed neither a significant main 
effect of Emotion F(1, 38) = 0.01, p = .93, ηp² < .01 nor a significant 
interaction F(1, 38) = 0.47, p = .50, ηp² = .01. The between factor 
was marginally significant, F(1, 38) = 3.27, p = .08, ηp² = .08, likely 
due to more pronounced amplitudes in the placebo (M = -6.33) 
compared with nocebo group (M = -3.71). The P2 component 
similarly revealed no significant effect of Emotion F(1,  38) = 
2.75, p = .11, ηp² < .07; however, the interaction of Group × Emotion 
was significant, F(1, 38) = 7.44, p = .01, ηp² < .16. Separate ANOVAs 
for each group showed a significant main effect of Emotion only 
for the placebo group, F(1, 19) = 6.64, p =  .02, ηp² =  .26, due to 
higher mean amplitudes following neutral (M = 14.02) compared 
with unpleasant pictures (M = 11.89). The same analysis returned 
a nonsignificant main effect of Emotion F(1, 19)  = 1.04, p = .32, ηp² 
= .05 for the nocebo group¸ see Figure 5.
FIGURE 2 | Mean pain intensity (left) and unpleasantness (right) ratings (+SEM) in the conditioning phase separately for stimulus intensity (high vs. low) and 
experimental group (nocebo vs. placebo). All within group comparisons and the between factor were significant (p < .05).
FIGURE 3 | Mean pain intensity (left) and unpleasantness (right) ratings (+SEM) in the test phase separately for picture category (neutral vs. unpleasant) and 
experimental group. All within group comparisons—except for pain intensity ratings of the nocebo group—and the between factor were significant (p < .05).
Placebo, Pain and EmotionReicherts et al.
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FIGURE 4 | The SEPs at the Cz electrode elicited by electrical pain stimuli during the conditioning phase. In the nocebo group (left), unpleasant pictures (red line) 
were paired with high-intensity pain stimuli, and in the placebo group, unpleasant pictures (green line) were paired with low-intensity pain stimuli. The gray lines 
represent neutral pictures, combined with either high- or low-intensity stimuli. The N1 (mean activity 75–125 ms) and the P2 (200–330 ms) components were 
significantly increased for high- compared with low-intensity pain stimuli in both experimental groups. All within group comparisons p < .05.
FIGURE 5 | (A) The SEPs at the Cz electrode elicited by electrical pain stimuli during the test phase. The N1 (75–125 ms) component showed no modulation by 
picture category or across groups. The P2 (200–330 ms) component instead was significantly decreased for electrical stimuli paired with unpleasant pictures in the 
placebo group only. (B) Scalp topography 220–300 ms for the difference of neutral and unpleasant pictures, separately for each group.
Placebo, Pain and EmotionReicherts et al.
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Visually Evoked Potentials During 
Conditioning and Test Phases
The 2 × 2 × 2 ANOVA for the analysis of the visually evoked 
LPPs revealed a significant main effect Phase F(1, 38) = 15.50, 
p = .001, ηp² = .29, which was the result of higher LPP amplitudes 
during the test compared with the conditioning phase (M = 
1.68 vs. M = 3.00). Furthermore, the significant main effect of 
Emotion F(1, 38) - 6.79, p = .01, ηp² = .15, was further qualified 
by a close to significant two-way interaction of Emotion × Group, 
F(1, 38) - 3.95, p = .054, ηp² = .09. Follow-up ANOVAs separately 
for each group revealed a significant main effect of Emotion F(1, 
19) - 13.39, p = .002, ηp² = .41 for the nocebo group, which is 
the result of elevated LPP amplitudes for unpleasant compared 
with neutral pictures. Interestingly, for the placebo group, the 
factor Emotion was far from being significant, F(1, 19) - 0.16, 
p = .70, ηp² < .01, see Figure 6. No other main effect or interaction 
reached significance, all ps > .22.
DISCUSSION
In the current study, we addressed the question whether a 
placebo/nocebo manipulation does alter the pain-enhancing 
effect of emotions elicited by unpleasant picture stimuli, and if 
so, neurophysiological correlates of emotions processing were 
changed accordingly. Results demonstrate lower pain ratings 
for unpleasant pictures introduced as placebo compared with 
neutral control pictures. Further, in the placebo group only, 
negative pictures led to reduced P2 amplitudes of the SEP. In the 
nocebo group, in line with classical findings, unpleasant pictures 
led to more pronounced LPP amplitudes than neutral pictures. 
In the placebo group instead, pleasant (placebo) and neutral 
(control) pictures led to similar neurophysiological responses, 
suggesting that the placebo manipulation already affected 
the processing of the emotional stimuli and, consequently, 
processing of the pain stimuli.
FIGURE 6 | (A) The LPPs at the Pz electrode averaged across conditioning and test phases, separately for neutral and unpleasant pictures and split by 
experimental group. The LPP between 700 and 1,000 ms (marked time window) was higher for unpleasant compared with neutral pictures in the nocebo group only 
(p = .002). (B) Scalp topography 700–1,000 ms for the difference of unpleasant and neutral pictures, separately for each group.
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Pain Modulation by Pictures Indicating 
Placebo Hypoalgesia or Nocebo 
Hyperalgesia
Pain ratings and neurophysiological pain responses during the 
conditioning phase of the experiment demonstrated a clear 
differentiation between the two stimulus intensities, which suggests 
a successful manipulation of the participants’ actual experience in 
line with the idea of reinforced expectations often used in placebo/
nocebo designs (16, 18, 41). The high-intensity stimuli were rated 
as more painful and unpleasant and evoked larger amplitudes of the 
N1 and P2 components of the SEP in both groups. Regarding the 
pain intensity ratings, the difference between neutral and unpleasant 
pictures tended to be even stronger in the placebo group, which 
is a first hint for a critical role of top–down-driven expectations 
rather than invariant effects of emotions on pain: following the 
concept of motivational priming (5, 42), one might have expected 
the pain-increasing effect of unpleasant pictures to be enhanced in 
the nocebo group. Instead, the placebo manipulation led to an even 
more pronounced differentiation, suggesting a more prominent role 
of the reinforced expectations than of the unpleasant pictures. The 
generally elevated pain ratings in the placebo group might to some 
degree be also the consequence of the experimental manipulation, 
but see the limitation section for further discussion.
The results from the test phase demonstrate even more clearly the 
interplay of our placebo/nocebo manipulation and the modulation 
of pain by emotions. Participants of the nocebo group demonstrated 
the well-known pain-augmenting effect of unpleasant pictures (43). 
The placebo group, however, reveals a completely reversed pattern. 
Here, the unpleasant pictures, introduced as having a pain-easing 
effect, led to significantly reduced pain intensity and unpleasantness 
ratings—of physically identical pain stimuli—compared with the 
neutral pictures. This indicates that the placebo expectation in 
combination with the conditioning procedure was able to reverse 
the pain-increasing effect of negative emotions, reflecting an efficient 
top–down control of pain processing.
There is a long-standing debate regarding the role of 
expectancy and learning, i.e., conditioning underlying the 
formation of placebo effects [see for instance (44, 16)], and 
some even question whether placebo effects per se are anything 
but conditioning effects and suggest to drop the concept in 
general (45). With regard to our present results, it is hard to 
tell whether the instruction in the beginning of the experiment or 
the placebo acquisition phase contributed to greater extent to the 
final placebo effect. A previous study by our group showed that in 
case of so to say psychologically mediated placebo/nocebo agents, 
both aspects are crucial. It might be interesting to test whether 
the present findings would replicate if only a conditioning 
procedure or placebo instruction was applied. Although research 
on expectancy effects on psychological pain modulation is 
rather sparse, the effect of placebo and nocebo expectations 
was repeatedly shown for pharmacological pain interventions. 
For instance, it was demonstrated that the same dosage of pain 
medication is more effective if it is administered in a so-called open 
fashion—that is, a patient is well aware of receiving a medication, 
which generates a robust expectation for analgesia—in contrast 
to a hidden application without explicit knowledge of the patient 
(46). On the contrary, a nocebo expectation is capable to abolish 
the effectiveness of a highly potent analgesic medication (47). 
Accordingly, the present findings suggest that the same might be 
true if the pain-modifying mechanism at question is based on 
psychological processes, here emotion-based pain modulation.
Placebo Expectations and Emotion 
Processing
Analysis of the LPPs, elicited by the picture stimuli, showed that 
participants in the nocebo group clearly differentiated between 
neutral and unpleasant pictures in line with previous studies 
on neurophysiological correlates of affective picture processing, 
which demonstrated a preferential processing of threatening 
stimuli (30, 31, 48, 49). However, the placebo group failed to 
exhibit discriminative LPPs for neutral versus unpleasant pictures, 
which might be due to an integration of emotional picture content 
and their alleged effect on pain. We suppose that the placebo 
manipulation changed the functional representation of the 
unpleasant pictures, since according to the instruction, those were 
now indicative for a positive outcome, which likely rendered them 
as less threatening. In accordance with this interpretation, Bradley 
and colleagues found that physiological responses following the 
presentation of emotional pictures change if picture valence—
positive vs. negative—operates as a cue for threat vs. safety, 
respectively (50). Threat cues, provoked stronger physiological 
defense reactions, irrespective of the emotional picture content. 
In a similar paradigm where positive and unpleasant pictures 
alternatingly served as threat or safety cues, analysis of the 
LPPs demonstrated elevated amplitudes for pictures indicating 
potential danger (51). Altogether, these findings suggest that 
affective picture processing and emotional responding is 
susceptible to a top–down-driven modulation of motivational/
functional significance. These results are further in line with a 
finding from research on emotion regulation, demonstrating that 
changing the meaning of an emotional relevant scene for instance 
by applying an alternative interpretation (reappraisal) leads to 
altered subjective and neurophysiological responses following 
picture processing (30, 52, 53).
Neurophysiological Pain Responses While 
Watching Pictures Indicating Placebo or 
Nocebo
SEPs during the test phase demonstrated no modulation of the 
early N1 component, neither in the nocebo group nor in the 
placebo group. However, previous studies found a significant 
modulation of the N1 solely for the comparison of unpleasant with 
positive pictures (3, 8). Accordingly, the contrast between neutral 
and unpleasant pictures was likely not strong enough, which might 
explain the lacking N1 modulation, especially in the nocebo group. 
Similarly, studies on placebo effects measuring neurophysiological 
responses to short laser beams found no modulation of early 
components of the LEP (54, 55). The P2 component instead 
was modulated by the picture category, but only in the placebo 
group, such that unpleasant compared with neutral (control) 
pictures led to a significantly reduced amplitude. This is in line 
with earlier findings demonstrating that emotional compared with 
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neutral pictures reduce the P2 following electrical stimuli (3, 8). 
Furthermore, studies investigating placebo effects on LEPs found 
that a placebo manipulation reduced the P2 component or N2/P2 
complex, respectively (54, 55). Given that participants in the placebo 
group showed little differentiation between the picture categories 
as indicated by similar LPP amplitudes, this might demonstrate an 
interference of emotion processing by the placebo manipulation. 
We conclude that the reduction of the P2 component likely is driven 
more strongly by a placebo effect than by the arousing content of 
the pictures. In the nocebo group, however, the instructed pain-
augmenting effect of unpleasant pictures did not provoke any conflict 
between picture content (negative) and functional significance 
(negative). Here, in line with previous studies on nocebo-like cueing 
effects reporting elevated LEPs (56), the experimental manipulation 
probably led to an increase of the P2 component during unpleasant 
picture presentation, which compensated the expected P2 decrease 
by high-arousing pictures found previously. Yet, the nocebo 
effect apparently was not strong enough to produce a significant 
potentiation of the P2 by unpleasant nocebo pictures, exceeding the 
responses following the neutral control pictures.
Limitations
Although the ratio of female and male subjects was equal within and 
across groups, due to the small total sample, a moderation of the 
reported findings by the participants’ gender cannot be excluded. 
Future studies should incorporate larger sample sizes to explore 
gender effects in more detail and to control for the sometimes-
high variability in placebo and nocebo designs. Furthermore, even 
though the experimental groups varied only very little with regard 
to the individual pain threshold and later on administered pain 
stimuli, participants of the placebo group reported higher pain 
intensity and unpleasantness ratings, in general, despite similar 
SEPs amplitudes. Results of the post-experimental ratings—
where participants of the placebo group indicated a relative pain-
increasing effect of neutral pictures compared with the nocebo 
group—might be suggestive for an overall overestimation of pain 
in the placebo group, leading to elevated pain ratings, see Table 
1. However, evidence for this interpretation is inconclusive and 
might be corroborated in future studies, obtaining measures of the 
participant’s expectation already in the beginning of the experiment. 
In a similar vein, we decided against trial-by-trial affective ratings 
of the emotional picture stimuli. This might have been informative 
with regard to the findings from the visual evoked potentials but, 
at the same time, led to excessive length of the whole experiment. 
Future studies should complement physiological affective responses 
by subjective measures of emotion and expand the stimulus set by a 
positive valence category. With regard to state affect, participants in 
the nocebo group presented somewhat higher anxiety scores, which 
may result from the nocebo instruction. The difference in state 
anxiety might have influenced the present findings; however, mean 
scores of both groups indicate very moderate levels of state anxiety. 
Lastly, the bar electrode used in the present design might have led 
to muscle contraction artifacts contaminating SEP findings. Given 
the very similar stimulation intensities between groups, artifacts 
might not explain group differences. The problem of potential 
artifacts could be addressed in futures studies for instance by using 
ring electrodes (57).
Conclusion and Outlook
The present study demonstrated an interaction of emotions and 
reinforced expectations on pain processing. We showed that a 
placebo manipulation (verbal instruction + placebo conditioning) is 
able to modulate and even reverse the genuine pain-increasing effect 
of unpleasant pictures. We assume that the placebo manipulation 
altered the processing of emotional pictures themselves, such 
that unpleasant pictures, expected to exert a positive effect on 
pain, were perceived as less arousing. This interpretation is in line 
with previous research demonstrating the modulatory influence 
of threat manipulations on physiological correlates of emotion 
processing (51, 58). These findings underline the important role of 
higher order expectations on pain processing and the effectiveness 
of psychological placebo effects as shown previously (18).
These processes deserve further explorations in future studies, 
investigating the interaction of placebo/nocebo expectations with 
other well-established emotional and cognitive factors impacting 
pain. For instance, it might be worthwhile to investigate whether 
a nocebo expectation of, e.g., pain exacerbation caused by highly 
demanding cognitive tasks, actually hampers the pain decrease 
following manipulations of attention allocation (59, 60). The 
same might be true for the modulation of pain by emotion 
regulation strategies such as reappraisal or suppression (61). 
A placebo vs. nocebo manipulation suggesting high vs. low 
effectiveness of pain regulation might block or even potentiate its 
pain-modifying capacities.
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